Tevogen Bio Holdings Inc. (NASDAQ:TVGNW – Get Free Report) was the target of a significant decline in short interest during the month of April. As of April 30th, there was short interest totaling 1,789 shares, a decline of 67.3% from the April 15th total of 5,479 shares. Based on an average daily trading volume, of 102,108 shares, the days-to-cover ratio is presently 0.0 days.
Tevogen Bio Price Performance
Tevogen Bio stock opened at $0.04 on Friday. The business’s fifty day simple moving average is $0.03 and its two-hundred day simple moving average is $0.04. Tevogen Bio has a 12 month low of $0.03 and a 12 month high of $0.08.
About Tevogen Bio
Tevogen Bio is a clinical-stage biotechnology company focused on developing allogeneic T cell receptor (TCR)-based immunotherapies for the treatment of cancer and infectious diseases. Leveraging a proprietary platform of engineered T cells, the company aims to deliver off-the-shelf cellular products that can recognize and eliminate disease-specific antigens without the need for patient-matched cell manufacturing.
The company’s pipeline encompasses programs targeting chronic viral infections, including hepatitis B virus and SARS-CoV-2, as well as cytomegalovirus, alongside oncology indications such as solid and hematological tumors.
Featured Stories
- Five stocks we like better than Tevogen Bio
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
- MarketBeat Week in Review – 05/11 – 05/15
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.
